Volume : 08, Issue : 09, September – 2021
Title:
58.ASSOCIATION OF SUPINE HYPERTENSION IN PATIENTS WITH PARKINSON’S DISEASE
Authors :
Dr Sara Akram Choudhry, Dr Neeraj Parkash, Dr Ayesha Akram Choudhry, Dr Komal Subhash, Dr Sandhiya Kumari, Dr Marium Faiz, Dr Mahpara Munir, Dr Saad Abdul Kareem
Abstract :
Introduction: Patients with primary chronic autonomic failure also often have supine hypertension.
Objectives: The main objective of the study is to evaluate the association of supine hypertension in patients with Parkinson’s disease.
Material and methods: This analytical study was conducted in Punjab Health department during June 2019 to December 2019. Blood pressure was measured noninvasively by using either a tonometric device placed on the radial pulse and calibrated against the brachial blood pressure measured by an automated cuff (Colin) or a photoplethysmographic device placed around a finger.
Results: The data was collected from 32 patients. Males were in majority 24 (75.0%) and most of them were above 60 years of age and females were 8 (25.0 %). The average age of patients was 62.5 years. The mean duration of the PD disease was 3.4 years. Nine (28.1%) had known hypertensive whereas 7 (21.9%) were taking ARBs. Conclusion: Supine hypertension is significantly associated with Parkinson’s disease, especially when the duration of disease is already long. Long term outcome and role of supine hypertension towards drug therapy response also needs to be elucidated.
Cite This Article:
Please cite this article in press Sara Akram Choudhry et al, Association Of Supine Hypertension In Patients With Parkinson’s Disease., Indo Am. J. P. Sci, 2021; 08(9).
Number of Downloads : 10
References:
REFERENCES:
1. Espay A, Peter L, Robert H, Aristide M, Mario M, Anthony L. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets. The Lancet Neurology 2016; 15: 954-66
2. Di Giovanni G, Di Matteo V, Esposito E. Birth, life and death of dopaminergic neurons in the substantia nigra. J Neural Transm Suppl 2009; 73:1
3. Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, et al. The past, present, and future of telemedicine for Parkinson’s disease. Mov Disord 2014; 29(7):871–83.
4. Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Curr Environ Health Rep (2017) 4(2):192–9.
5. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J: Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011; 26(suppl 1):S1–S58.
6. Liu R, Guo X, Park Y, Wang J, Huang X, Hollenbeck A, Blair A, Chen H: Alcohol consumption, types of alcohol, and Parkinson’s disease. PLoS One 2013; 8:e66452.
7. Zhang D, Jiang H, Xie J: Alcohol intake and risk of Parkinson’s disease: a meta-analysis of observational studies. Mov Disord 2014; 29: 819–822.
8. Etminan M, Gill SS, Samii A: Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 2005; 4: 362–365.
9. Li AA, Mink PJ, McIntosh LJ, Teta MJ, Finley B: Evaluation of epidemiologic and animal data associat- ing pesticides with Parkinson’s disease. J Occup Environ Med 2005; 47: 1059– 1087.
10. Gagne JJ, Power MC: Anti-inflammatory drugs and risk of Parkinson disease: a metaanalysis. Neurology 2010; 74: 995–1002.